Nippon Shinyaku secures US commercialization rights for AB2 Bio’s Tadekinig alfa

Reuters2026/07/30 06:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nippon Shinyaku exercised option rights under its January 2025 agreement with AB2 Bio to commercialize Tadekinig alfa in the U.S.
Deal grants exclusive U.S. commercialization rights for monogenic IL-18 driven hyperinflammatory syndrome in patients with NLRC4 and XIAP mutations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nippon Shinyaku secures US commercialization rights for AB2 Bio’s Tadekinig alfa

You may also like

Crypto prices